Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 3274-3282, December 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldenberg, G. J.
Right arrow Articles by Cormack, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldenberg, G. J.
Right arrow Articles by Cormack, D. V.

Mechanism of Cyclophosphamide Transport by L5178Y Lymphoblasts in Vitro1

Gerald J. Goldenberg2, H. Bernard Land and Douglas V. Cormack

Department of Medicine, University of Manitoba, and The Manitoba Institute of Cell Biology [G. J. G., H. B. L.] and Department of Physics, The Manitoba Cancer Treatment and Research Foundation and the Department of Medical Microbiology, University of Manitoba [D. V. C.], Winnipeg, Manitoba, R3E 0V9, Manitoba, Canada

Mechanism of transport of the alkylating agent cyclophosphamide-14C was investigated in L5178Y lymphoblasts in vitro. A time course of cyclophosphamide uptake showed a rapid, initial phase, probably due to binding of drug to the cell surface. Subsequent uptake into the cells was carrier mediated and consisted of two components. Analysis of cyclophosphamide uptake over a 40-fold range of drug concentration showed biphasic kinetics with evidence of saturation only at low drug concentrations whereas, at high drug levels, uptake occurred by a second transport system that was technically nonsaturable. After correction for binding and the interaction of two-component transport, kinetic parameters for low-dose transport consisted of a Michaelis constant Km (mean ± S.E.) of 0.39 ± 0.03 mM and a transport capacity Vmax of 0.49 ± 0.07 x 10-17 moles/min/cell. At high-dose cyclophosphamide transport, the apparent Km was 75 ± 29 mM, and the Vmax was 49 ± 14 x 10-17 moles/min/cell. Both low- and high-dose cyclophosphamide transport were temperature sensitive and partially dependent on sodium. In addition, low-dose transport was inhibited by oligomycin and cyanide. Other alkylating agents and several naturally occurring substrates did not inhibit cyclophosphamide transport; thus, a native substrate was not identified for the cyclophosphamide carrier, and transport was by a mechanism separate from that of other alkylating agents.

Evidence that low-dose cyclophosphamide transport was mediated by a facilitated diffusion process was that uptake obeyed saturation kinetics, was temperature and sodium dependent, was partially dependent on metabolic energy, and cell/medium concentration gradients did not exceed unity. Although high-dose drug uptake failed to show saturation kinetics, the demonstration of temperature and sodium dependence also suggested that high-dose uptake may be carrier mediated.

Cyclophosphamide uptake by chick embryo liver cells was examined also; uptake was temperature sensitive and exhibited biphasic kinetics similar to that observed in L5178Y cells, suggesting a similar mechanism of drug transport in normal liver and leukemic cells.

1 This work was supported by a grant from the National Cancer Institute of Canada.

2 Clinical Research Associate of the National Cancer Institute of Canada.

Received 6/ 3/74. Accepted 8/27/74.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
L. Panasci, J.-P. Paiement, G. Christodoulopoulos, A. Belenkov, A. Malapetsa, and R. Aloyz
Chlorambucil Drug Resistance in Chronic Lymphocytic Leukemia: The Emerging Role of DNA Repair
Clin. Cancer Res., March 1, 2001; 7(3): 454 - 461.
[Abstract] [Full Text]


Home page
Journal of Bioactive and Compatible PolymersHome page
C. V. Uglea, I. N. Albu, A. Vatajanu, M. Croitoru, D. Iurea, M. Isac, and R. M. Ottenbrite
Polyanionic Polymers. I. Synthesis, Characterization, and Potential Medical Applications of Benzocaine Modified Carboxymethylcellulose
Journal of Bioactive and Compatible Polymers, January 1, 1994; 9(4): 448 - 461.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.